CDK4 and hepatocellular carcinoma: Other Cdks could be targets too, whereas PD-0332991 a Cdk4/6 inhibitor halts proliferation of hepatocytes and HCC xenografts in vivo [227] and is being tested in phase 2 clinical trials as replacement drug for patients intolerant to Sorafenib treatment.